AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MEMPHASYS LIMITED. Board/Management Information 2015

Sep 9, 2015

65314_rns_2015-09-09_a6905746-f1c2-49a6-b1b6-e7a34fd76c5d.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [196 x 96] intentionally omitted <==

ASX Release

APPOINTMENT OF ANDREW GOODALL TO THE BOARD OF PRIME BIOLOGICS PTE LTD

Sydney, Thursday 10 Sept 2015

NuSep Holdings Limited (ASX: NSP, the Company or NuSep ) advises that Mr Andrew Goodall has been appointed to the board of PrIME Biologics Pte Ltd as NuSep’s representative.

PrIME Biologics is a Singapore-based investment held by NuSep, focussed on applying the technology originally developed by NuSep to fractionate blood plasma.

Mr Goodall is a non-executive director of NuSep and a major shareholder of the Company. He replaces NuSep’s Executive Chairman and NuSep’s former representative on the board of PrIME Biologics Pte Ltd, Ms Alison Coutts.

For further information please contact:

Alison Coutts Executive Chairman +61 2 8415 7300 [email protected]

NuSep Holdings Ltd 30 Richmond Rd Homebush NSW 2140